Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS Mutation Detection with (2S,4R)-4-[18F]FGln for Noninvasive PDAC Diagnosis.

Molecular pharmaceutics - 1 Apr 2024

Liu Song, Liu Futao, Hou Xingguo, Zhang Qian, Ren Ya'nan, Zhu Hua, Yang Zhi, Xu Xiaoxia

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis and nonspecific symptoms and progresses rapidly, is the most common pancreatic cancer type. Inhibitors targeting KRAS G12D and G12C mutations have been pivotal in PDAC treatment. Cancer cells with different KRAS mutations exhibit various degrees of glutamine dependency; in particular, cells with KRAS G12D mutations exhibit increased glutamine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to MIA gene
Share to Glutamine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Tissue Distribution

Source

Open in PubMed Open full text

Identifiers

PMID: 38456403
DOI: 10.1021/acs.molpharmaceut.4c00082
PMCID: PMC10989612

Genes

KRAS
MIA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS Mutation Detection with (2S,4R)-4-[18F]FGln for Noninvasive PDAC Diagnosis.PMID 38456403Read ↗

Loss of Heterozygosity for KrasG12D Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF-2α-c-Myc-Regulated Glutamine Metabolism.Semantic proximity Read ↗

Correlation of MRI characteristics with KRAS mutation status in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

KRAS: feeding pancreatic cancer proliferation.Semantic proximity Read ↗

PHGDH is a targetable driver of PDAC progressionSemantic proximity Read ↗

Pyruvate Kinase Activity Regulates Cystine Starvation Induced Ferroptosis through Malic Enzyme 1 in Pancreatic Cancer CellsSemantic proximity Read ↗

Loss of heterozygosity for KrasG12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivitySemantic proximity Read ↗

Simultaneous inhibition of PFKFB3 and GLS1 selectively kills KRAS-transformed pancreatic cells.Semantic proximity Read ↗

Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor TherapySemantic proximity Read ↗

Multimodal Molecular Imaging of Integrin αvβ3 for In Vivo Detection of Pancreatic CancerSemantic proximity Read ↗

Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo.Semantic proximity Read ↗

Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.